Plenteous Pharmaceuticals Limited - Due diligence report

A 360° intelligence report on Plenteous Pharmaceuticals Limited: trust score, financial health, credit view, compliance, directors, growth a…

2008-12-11 Delhi, Delhi Active Unlisted Active Compliant
Share
Connect MCP
PP Plenteous Pharmaceuticals Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Plenteous Pharmaceuticals Limited — 360° Intelligence Report

Generated from MCA filings & public records
64/100
Trust Score
Moderate

Plenteous Pharmaceuticals Limited is assessed as Moderate with a Trust Score of 64/100. Plenteous Pharmaceuticals Limited is an active public limited indian non-government company incorporated in 2008, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and high financial risk profile.

Report generated on 17 Aug 2026 from the latest processed filings. Plenteous Pharmaceuticals Limited snapshot & full profile →

Financial Health › Caution
Overall Assessment CautionWeakNeutralGoodStrong Good
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
64/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
93/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
10/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
45/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
70/100
Revenue, profit, asset and hiring momentum.
Distress ScoreCaution Indicated
40/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 45/100 Caution Indicated
  • Negative operating earnings - debt service depends on external support.
  • Working-capital cover adequate.

Charges position: 1 open (5.00 cr) · 2 satisfied (42.00 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Jp Morgan Chase Bank, N.A.1 48.0 cr
Hdfc Bank Limited1 48.0 cr
Icici Bank Limited1 48.0 cr
Compliance Score: 93/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • Litigation present in 1 court forum(s).
  • 6 active GST registration(s).
Legal cases on record (1)
05

Director Intelligence

Stability score: 90/100
NameDIN / PANDesignationAppointedTenureDIN status
DHARA BALLABH TIWARI 01234567 Director 01/04/2018 6 yrs Approved
POOJA SHARMA 01234567 Director 01/04/2018 6 yrs Approved
NEETIKA GOEL 01234567 Director 01/04/2018 6 yrs Approved
  • 3 directors on the board.
  • No disqualified or deactivated DINs.
  • 1 director exit(s) in the last 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Akums Drugs And Pharmaceuticals Limited
Subsidiaries
-
Group entities
-
Capital events
0 allotment(s) · 2 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Group entityRelationship% held
Akums Drugs And Pharmaceuticals Limited Holding Company 74.00%

Key managerial personnel: POOJA SHARMA (Whole-time director)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 70 · Distress 40
Growth signals & trust indicators
Revenue acceleration: +38% over 4 year(s).
Operating for 17+ years.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Losses deepening year-on-year.
Negative net worth.
1 open charge(s) registered - assets are encumbered.
1 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence68/100
Review suggested
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 3 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment46/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 1 open charge(s) of 5.00 cr already registered.
  • Compliance record supports lending.
Investor view48/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • 1 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
11 May 2025
Last AGM held
Annual general meeting
10 May 2025
Director ceased
NEETIKA GOEL
24 Apr 2025
Charge satisfied
Jp Morgan Chase Bank, N.A.
31 Mar 2025
Latest balance sheet
Filed with ROC
06 Nov 2024
Director appointed
NEETIKA GOEL (Director)
17 Jun 2023
Director ceased
KUSUM PAL SHARMA
10 Mar 2023
Charge created
Jp Morgan Chase Bank, N.A. - 40.00 cr
03 Jul 2022
Director ceased
BINOD KUMAR YADAV
24 Mar 2022
Director ceased
MAHESH MALHOTRA
29 Jun 2019
Charge created
Hdfc Bank Limited - 5.00 cr
25 Mar 2019
Charge satisfied
Icici Bank Limited
03 Jun 2018
Director ceased
DHARA BALLABH TIWARI
Director ceased
POOJA SHARMA
24 Nov 2017
Director appointed
POOJA SHARMA (Whole-time director)
Director ceased
SANJAY CHANDRA VARMA
10

Key Observations

Auto-generated from the data above
Revenue grew 1.42 over the last 4 financial year(s).
Net profit margin moved from 2.1x to 24%.
Compliance record is strong - status, filings and flags are clean.
3 active director(s) / partner(s); board looks stable and experienced.
6 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Cryoviva Biotech U85195DL2005PTC137768 New Delhi, Delhi, India
Muthoot Health Care U85110KL2013PTC034223 Pathanamthitta, Kerala, India
Madhavbaug L73100PN1999PLC013509 Pune, Maharashtra, India
Kongunad Hospitals Private Limited U85110TZ1991PTC003139 Coimbatore, Tamil Nadu, India
Sharp Sight U85110DL2002PTC116372 New Delhi, Delhi, India
Vizag Hospital And Cancer Research Centre Pvt Ltd U85110AP1986PTC006235 A.P, Andhra Pradesh, India
Sonoscan U85110WB2008PTC127225 Malda, West Bengal, India
Eyeqindia U85121DL2006PTC152865 Delhi, Delhi, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Plenteous Pharmaceuticals Limited before audits and certifications: compliance score 93/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Plenteous Pharmaceuticals Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 45/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score 70/100, margin trends, ownership structure and peer set for Plenteous Pharmaceuticals Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Review suggested. Trust score 64/100, distress signals and MSME payment-delay disclosures - know whether Plenteous Pharmaceuticals Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Plenteous Pharmaceuticals Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Plenteous Pharmaceuticals Limited an active company?

Plenteous Pharmaceuticals Limited has MCA status “Active” with a compliance score of 93/100 (Low Risk).

Is Plenteous Pharmaceuticals Limited financially healthy?

Plenteous Pharmaceuticals Limited has a Financial Health Score of 10/100 (Caution Indicated) based on its filed financial statements.

Should I do business with Plenteous Pharmaceuticals Limited?

Its overall Trust Score is 64/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Plenteous Pharmaceuticals Limited?

The ultimate holding entity is Akums Drugs And Pharmaceuticals Limited. 3 active director(s) are on record.

Does Plenteous Pharmaceuticals Limited have loans or charges against its assets?

1 open charge(s) are registered against its assets, and 2 earlier charge(s) stand satisfied.

Is Plenteous Pharmaceuticals Limited up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 93/100 (Low Risk).

Is it risky to lend to Plenteous Pharmaceuticals Limited?

Its Credit Risk Score is 45/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.